Contrive Datum Insights has published "Swine Vaccines Market Size, Share & Industry Analysis, By Vaccine type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Recombinant/Subunit Vaccines, DNA/Nucleic Acid Vaccines, Toxoid Vaccines), Target disease (Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), Classical Swine Fever (CSF), African Swine Fever (ASF), Swine Influenza, Mycoplasma Hyopneumoniae (M. Hyo), Actinobacillus Pleuropneumoniae (APP), Porcine Epidemic Diarrhea Virus (PEDV) & Enteric Diseases, Pseudorabies (Aujeszky's Disease), Porcine Parvovirus & Erysipelas), Valency (Monovalent Vaccines, Bivalent Vaccines, Multivalent/Combination Vaccines), Route of administration (Intramuscular Injection, Subcutaneous Injection, Intranasal Administration, Oral Administration), Production stage/animal class (Sows & Gilts, Boars, Suckling Piglets, Weaners, Growers & Finishers), Distribution channel (Veterinary Hospitals & Clinics, Retail Pharmacies/Agrovet Stores, Direct/Institutional Sales to Integrators, e-Commerce/Online Platforms), End user/farm type (Commercial/Industrial Farms, Integrated Pork Producers, Smallholder/Backyard Producers, Veterinary Research Institutes & Laboratories), Technology platform (Conventional/Cell-Culture Based Platforms, Vector-Based/Recombinant Platforms, mRNA/Nucleic Acid-Based Platforms), Dose format/packaging (Single-Dose Vials, Multi-Dose Vials, Pre-Filled Syringes), Vaccination program type (Core/Routine Herd Vaccination, Outbreak/Emergency Response Vaccination, Custom/Autogenous Vaccination Programs), and Regional Forecast, 2026-2034". The study sizes the global swine vaccines market at USD 1.85 billion in 2025 and projects growth from USD 1.985 billion in 2026 to USD 3.411 billion by 2034, a compound annual growth rate of 7% across the forecast period.
Swine vaccines are biological products administered to pigs to prevent or control viral and bacterial diseases affecting reproduction, respiratory health and growth performance across commercial and smallholder herds. They are formulated as inactivated, live attenuated, recombinant or nucleic-acid based products and are delivered by injection, intranasal spray or oral dosing depending on the target pathogen and production stage. Buyers range from large integrated pork producers and commercial farm operators purchasing directly from manufacturers to independent veterinary clinics, agrovet retailers and smallholder producers sourcing through local distribution channels.
Commercialization of African Swine Fever vaccines and expanded biosecurity-driven vaccination mandates
Commercialization of African Swine Fever vaccines and expanded biosecurity-driven vaccination mandates is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7% a year, the vaccine type lines exposed to it move fastest: DNA/Nucleic Acid Vaccines compounds at 13.95%, taking its share of revenue from 5.02% to 9% and its value from USD 0.093 billion to USD 0.307 billion.
Where the forecast could be beaten: bull case assumes faster regulatory clearance and publicly supported rollout of African Swine Fever vaccines across additional Asia Pacific markets, sustaining higher vaccination coverage growth through the forecast period. The study puts that case at USD 3.813 billion in 2034, against USD 3.411 billion in the base.
Against that, bear case assumes slower antigen approval timelines and continued herd consolidation delays that keep smallholder and backyard vaccination penetration close to current levels through 2034. On that reading 2034 revenue stops at USD 3.046 billion. The weight of the problem sits in Inactivated (Killed) Vaccines: 44.98% of 2025 revenue growing at 4.98%, well under the market's 7%.
Key Players Compete on Inactivated (Killed) Vaccines Volume and DNA/Nucleic Acid Vaccines Growth
Competition in the global swine vaccines market runs along the vaccine type axis, not the regional one. Inactivated (Killed) Vaccines holds 44.98% of 2025 revenue at USD 0.833 billion and remains the largest line through 2034 at 37.99%, making it the position hardest for a challenger to take. DNA/Nucleic Acid Vaccines, growing at 13.95%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 1.85 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Vaccine type | Inactivated (Killed) Vaccines | 44.98% · USD 0.833 billion | — |
| Target disease | Porcine Reproductive and Respiratory Syndrome (PRRS) | 21.98% · USD 0.407 billion | African Swine Fever (ASF) 17.13% |
| Valency | Monovalent Vaccines | 40% · USD 0.74 billion | Multivalent/Combination Vaccines 9.88% |
| Route of administration | Intramuscular Injection | 55% · USD 1.018 billion | Intranasal Administration 11.26% |
| Production stage/animal class | Sows & Gilts | 32% · USD 0.592 billion | Suckling Piglets 9.1% |
| Distribution channel | Direct/Institutional Sales to Integrators | 45% · USD 0.833 billion | e-Commerce/Online Platforms 14.59% |
| End user/farm type | Integrated Pork Producers | 38% · USD 0.703 billion | Veterinary Research Institutes & Laboratories 9.72% |
| Technology platform | Conventional/Cell-Culture Based Platforms | 64.99% · USD 1.203 billion | mRNA/Nucleic Acid-Based Platforms 15.61% |
| Dose format/packaging | Multi-Dose Vials | 58% · USD 1.073 billion | Pre-Filled Syringes 11.97% |
| Vaccination program type | Core/Routine Herd Vaccination | 72% · USD 1.332 billion | Outbreak/Emergency Response Vaccination 10.19% |
- Asia Pacific was the largest region in 2025, holding 38% of global revenue at USD 0.703 billion and reaching USD 1.399 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 38% in 2025 to 41% in 2034, with revenue growing from USD 0.703 billion to USD 1.399 billion.
- Middle East and Africa stays the smallest contributor across the period: 6% of revenue in 2025 and 6% in 2034.
- DNA/Nucleic Acid Vaccines is projected to grow at 13.95% over the forecast period, the fastest of any vaccine type line.
- China is the largest single country market at USD 0.387 billion in 2025, 20.9% of global revenue.
The report segments the market across ten axes; by vaccine type, and by target disease, valency, route of administration, production stage/animal class, distribution channel, end user/farm type, technology platform, dose format/packaging and vaccination program type; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 3.046 billion and USD 3.813 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.